17 alpha-hydroxyprogesterone caproate has been researched along with alvimopan anhydrous in 1 studies
| Studies (17 alpha-hydroxyprogesterone caproate) | Trials (17 alpha-hydroxyprogesterone caproate) | Recent Studies (post-2010) (17 alpha-hydroxyprogesterone caproate) | Studies (alvimopan anhydrous) | Trials (alvimopan anhydrous) | Recent Studies (post-2010) (alvimopan anhydrous) |
|---|---|---|---|---|---|
| 517 | 88 | 251 | 169 | 25 | 93 |
| Protein | Taxonomy | 17 alpha-hydroxyprogesterone caproate (IC50) | alvimopan anhydrous (IC50) |
|---|---|---|---|
| Mu-type opioid receptor | Homo sapiens (human) | 0.0026 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 5.0119 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for 17 alpha-hydroxyprogesterone caproate and alvimopan anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |